Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited.

The trial is conducted at the Clinical Research Center for Hair and Skin Science in Berlin and Bioskin, Hamburg, Germany. The objective is to investigate the safety and effect of different doses of the drug candidate FOL-005 on scalp.

FOL-005

FOL-005 is a modified, short version of the endogenous protein, osteopontin. In the recently completed phase I/IIa study, FOL-005 was shown to be a safe and effective treatment, with 3 out of 4 subjects responding with increased hair growth. In the ongoing study, the patients are treated with different doses of the drug candidate FOL-005 or placebo, administered as injections at two sites on the scalp. Injections are given three times per week for three months. The study is expected to be completed in late 2018.

“We are very pleased to note that all patients are recruited and that we are slightly ahead of plan. Our intention with the current clinical trial is to confirm recently documented results, where we saw both good effect and safety with FOL-005, as well as a very high patient response. We are looking forward to being able to present the results by the end of this year,” says Jan Alenfall, CEO